Do analysts recommend BRNS or SKYE?

Barinthus Biotherapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 440.47%. Given Barinthus Biotherapeutics' higher possible upside, equities research analysts plainly believe Barinthus Biotherapeutics is more favorable than Skye Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Barinthus Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Skye Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, BRNS or SKYE?

Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Barinthus Biotherapeutics N/A N/A -$66.43M -$1.03 N/A Skye Bioscience N/A N/A -$55.92M -$10.16 N/A

Is BRNS or SKYE more profitable?

Barinthus Biotherapeutics' return on equity of -59.15% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -59.15% -43.80% Skye Bioscience N/A -329.08% -201.79%

Do analysts recommend RNAZ or SKYE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Skye Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, RNAZ or SKYE?

Skye Bioscience is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransCode Therapeutics N/A N/A -$34.66M -$52.37 N/A Skye Bioscience N/A N/A -$55.92M -$10.16 N/A

Is RNAZ or SKYE more profitable?

Skye Bioscience's return on equity of -329.08% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -37.46% Skye Bioscience N/A -329.08% -201.79%

Do analysts prefer SKYE or MDXH?

MDxHealth has a consensus target price of $2.17, suggesting a potential upside of 258.78%. Given MDxHealth's stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than Skye Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts prefer MCRB or SKYE?

Seres Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 534.33%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Seres Therapeutics is more favorable than Skye Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Skye Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer QNCX or SKYE?

Quince Therapeutics presently has a consensus target price of $189.88, suggesting a potential upside of 493.17%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Quince Therapeutics is more favorable than Skye Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 2 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.64 Skye Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, QNCX or SKYE?

Quince Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quince Therapeutics N/A N/A -$83.98M -$156.71 N/A Skye Bioscience N/A N/A -$55.92M -$10.16 N/A

Is QNCX or SKYE more profitable?

Quince Therapeutics' return on equity of 0.00% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -133.84% Skye Bioscience N/A -329.08% -201.79%

Skye Bioscience (SKYE) Competitors

$1.53 -0.05 (-3.16%)

Closing price 04:00 PM Eastern

Extended Trading

$1.59 +0.06 (+4.18%)

As of 06:29 PM Eastern

Compare

SKYE vs. BRNS, RNAZ, MDXH, MCRB, and QNCX

Should you buy Skye Bioscience stock or one of its competitors? Skye Bioscience's main competitors and comparable companies include Barinthus Biotherapeutics (BRNS), TransCode Therapeutics (RNAZ), MDxHealth (MDXH), Seres Therapeutics (MCRB), and Quince Therapeutics (QNCX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Skye Bioscience compare to Barinthus Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Skye Bioscience (NASDAQ:SKYE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Barinthus Biotherapeutics has a beta of -0.37, indicating that its share price is 137% less volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.86, indicating that its share price is 186% more volatile than the broader market.

Barinthus Biotherapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 440.47%. Given Barinthus Biotherapeutics' higher possible upside, equities research analysts plainly believe Barinthus Biotherapeutics is more favorable than Skye Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Skye Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$10.16	N/A

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Skye Bioscience had 1 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 1 mentions for Skye Bioscience and 0 mentions for Barinthus Biotherapeutics. Skye Bioscience's average media sentiment score of 1.82 beat Barinthus Biotherapeutics' score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Skye Bioscience	Very Positive

Barinthus Biotherapeutics' return on equity of -59.15% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
Skye Bioscience	N/A	-329.08%	-201.79%

Summary

Barinthus Biotherapeutics beats Skye Bioscience on 6 of the 11 factors compared between the two stocks.

How does Skye Bioscience compare to TransCode Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Skye Bioscience (NASDAQ:SKYE) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Skye Bioscience is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$10.16	N/A

21.1% of Skye Bioscience shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by insiders. Comparatively, 6.2% of Skye Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, TransCode Therapeutics had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 2 mentions for TransCode Therapeutics and 1 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 1.82 beat TransCode Therapeutics' score of 0.91 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
TransCode Therapeutics	Positive
Skye Bioscience	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Skye Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

TransCode Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.86, indicating that its share price is 186% more volatile than the broader market.

Skye Bioscience's return on equity of -329.08% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-37.46%
Skye Bioscience	N/A	-329.08%	-201.79%

Summary

Skye Bioscience beats TransCode Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Skye Bioscience compare to MDxHealth?

Skye Bioscience (NASDAQ:SKYE) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

MDxHealth has higher revenue and earnings than Skye Bioscience. MDxHealth is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$10.16	N/A
MDxHealth	$114.02M	0.26	-$33.52M	-$0.72	N/A

MDxHealth has a consensus target price of $2.17, suggesting a potential upside of 258.78%. Given MDxHealth's stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than Skye Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Skye Bioscience has a beta of 2.86, suggesting that its stock price is 186% more volatile than the broader market. Comparatively, MDxHealth has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market.

21.1% of Skye Bioscience shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, MDxHealth had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 2 mentions for MDxHealth and 1 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 1.82 beat MDxHealth's score of 0.61 indicating that Skye Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Skye Bioscience	Very Positive
MDxHealth	Positive

Skye Bioscience has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-329.08%	-201.79%
MDxHealth	-33.46%	N/A	-24.25%

Summary

MDxHealth beats Skye Bioscience on 9 of the 15 factors compared between the two stocks.

How does Skye Bioscience compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Skye Bioscience (NASDAQ:SKYE) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Seres Therapeutics has higher revenue and earnings than Skye Bioscience. Seres Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	34.09	$5.70M	-$2.43	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$10.16	N/A

In the previous week, Seres Therapeutics had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 2 mentions for Seres Therapeutics and 1 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 1.82 beat Seres Therapeutics' score of 0.60 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Seres Therapeutics	Positive
Skye Bioscience	Very Positive

Skye Bioscience has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Seres Therapeutics' return on equity of -114.82% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Skye Bioscience	N/A	-329.08%	-201.79%

Seres Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 534.33%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Seres Therapeutics is more favorable than Skye Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Skye Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Seres Therapeutics has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.86, indicating that its stock price is 186% more volatile than the broader market.

Summary

Seres Therapeutics beats Skye Bioscience on 10 of the 15 factors compared between the two stocks.

How does Skye Bioscience compare to Quince Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Skye Bioscience (NASDAQ:SKYE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

Quince Therapeutics' return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
Skye Bioscience	N/A	-329.08%	-201.79%

Quince Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.86, indicating that its share price is 186% more volatile than the broader market.

Quince Therapeutics presently has a consensus target price of $189.88, suggesting a potential upside of 493.17%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Quince Therapeutics is more favorable than Skye Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.64
Skye Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Quince Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$10.16	N/A

In the previous week, Quince Therapeutics had 7 more articles in the media than Skye Bioscience. MarketBeat recorded 8 mentions for Quince Therapeutics and 1 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 1.82 beat Quince Therapeutics' score of 0.65 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Quince Therapeutics	Positive
Skye Bioscience	Very Positive

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 5.6% of Quince Therapeutics shares are owned by company insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Quince Therapeutics beats Skye Bioscience on 8 of the 14 factors compared between the two stocks.

Get Skye Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SKYE vs. The Competition

Export

Metric	Skye Bioscience	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.78M	$3.82B	$7.16B	$13.16B
Dividend Yield	N/A	3.65%	2.52%	20.73%
P/E Ratio	-0.15	12.90	275.97	25.79
Price / Sales	N/A	1,176.95	617.33	101.37
Price / Cash	N/A	39.46	27.30	36.12
Price / Book	0.31	16.95	10.68	6.03
Net Income	-$55.92M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-5.56%	-4.83%	-3.17%	-3.04%
1 Month Performance	-25.00%	-12.20%	-6.61%	-5.16%
1 Year Performance	-87.29%	8.87%	3.69%	-2.48%

Skye Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SKYE Skye Bioscience	1.6143 of 5 stars	$1.53 -3.2%	N/A	-88.6%	$6.78M	N/A	N/A	12	Positive News Gap Up
BRNS Barinthus Biotherapeutics	1.7296 of 5 stars	$0.74 flat	$4.00 +440.5%	N/A	$30.23M	N/A	N/A	107
RNAZ TransCode Therapeutics	1.0947 of 5 stars	$1.78 +1.1%	N/A	-88.5%	$29.80M	N/A	N/A	12	Gap Up
MDXH MDxHealth	2.7526 of 5 stars	$0.60 +0.5%	$2.17 +261.2%	-85.2%	$29.55M	$114.02M	N/A	364
MCRB Seres Therapeutics	2.5408 of 5 stars	$2.90 +1.8%	$17.00 +486.2%	-86.0%	$28.63M	$790K	N/A	66

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SKYE) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Skye Bioscience (SKYE) Competitors

SKYE vs. BRNS, RNAZ, MDXH, MCRB, and QNCX

How does Skye Bioscience compare to Barinthus Biotherapeutics?

Summary

How does Skye Bioscience compare to TransCode Therapeutics?

Summary

How does Skye Bioscience compare to MDxHealth?

Summary

How does Skye Bioscience compare to Seres Therapeutics?

Summary

How does Skye Bioscience compare to Quince Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE vs. The Competition

Skye Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Skye Bioscience (SKYE) Competitors

SKYE vs. BRNS, RNAZ, MDXH, MCRB, and QNCX

How does Skye Bioscience compare to Barinthus Biotherapeutics?

Which has more risk & volatility, BRNS or SKYE?

Do analysts recommend BRNS or SKYE?

Which has stronger earnings & valuation, BRNS or SKYE?

Do insiders & institutionals hold more shares of BRNS or SKYE?

Does the media prefer BRNS or SKYE?

Is BRNS or SKYE more profitable?

Summary

How does Skye Bioscience compare to TransCode Therapeutics?

Which has better valuation & earnings, RNAZ or SKYE?

Do insiders and institutionals hold more shares of RNAZ or SKYE?

Does the media prefer RNAZ or SKYE?

Do analysts recommend RNAZ or SKYE?

Which has more volatility & risk, RNAZ or SKYE?

Is RNAZ or SKYE more profitable?

Summary

How does Skye Bioscience compare to MDxHealth?

Which has higher valuation & earnings, SKYE or MDXH?

Do analysts prefer SKYE or MDXH?

Which has more risk & volatility, SKYE or MDXH?

Do institutionals and insiders have more ownership in SKYE or MDXH?

Does the media favor SKYE or MDXH?

Is SKYE or MDXH more profitable?

Summary

How does Skye Bioscience compare to Seres Therapeutics?

Which has preferable valuation & earnings, MCRB or SKYE?

Does the media prefer MCRB or SKYE?

Is MCRB or SKYE more profitable?

Do analysts prefer MCRB or SKYE?

Do institutionals and insiders hold more shares of MCRB or SKYE?

Which has more volatility and risk, MCRB or SKYE?

Summary

How does Skye Bioscience compare to Quince Therapeutics?

Is QNCX or SKYE more profitable?

Which has more volatility & risk, QNCX or SKYE?

Do analysts prefer QNCX or SKYE?

Which has stronger earnings and valuation, QNCX or SKYE?

Does the media favor QNCX or SKYE?

Do insiders and institutionals hold more shares of QNCX or SKYE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE vs. The Competition

Skye Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools